Skip to main content
Caplight Logo









Arrakis Bio

Arrakis Bio

Private
IsraelHealthcare & Life Scienceshttps://www.arrakis.bio/

Last Round

Series A

Jul 22, 2026

Est. Valuation

$140M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

Arrakis Bio is a biotechnology company that develops animal-free, high-quality human collagen and gelatin for medical, aesthetic, and biomedical applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

RNA-targeted small moleculerSMdrug discoverybiotechnologyRNA therapeuticssmall molecule drugsundruggable targetsdrug discovery platformbiopharmaRNA structuremedicinal chemistryAI-augmented drug discoverycomputational biologydrug development partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Arrakis Bio Comparables

Compare Arrakis Bio with similar companies based on industry and business-model similarity.

Arrakis Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Expansion Therapeutics
89%
Ribometrix
88%
xFOREST Therapeutics Co., Ltd.
86%

Arrakis Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 22, 2026
SeedJul 19, 2023

Key People

Founding team and executive leadership

Dalia Rosin

CTO And Co-founder

Founding Team

Fabian Trumper

Co-Founder CEO

Founding Team

Arrakis Bio Investors

Notable investors and investment history

Arrakis Bio investors
InvestorRounds
Global Founders CapitalSeries A
Blossom CapitalSeries A
FLORA VenturesSeed
AccelSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 22, 2026

    $30M round led by Blossom Capital.

  • Jul 19, 2023

    Seed round led by FLORA Ventures.

Arrakis Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Arrakis Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Arrakis Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Employee Range4
Year Founded2023
Last FundingJul 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?